For the purpose of creating a more potent treatment for sorafenib-resistant malignancies, these findings call for additional research on the combination of treating HCC-resistant cells with GSK1059615 (a PI3K/mTOR inhibitor) in vivo [290]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.